[go: up one dir, main page]

AU2002232447A1 - Method of enhancing lymphocyte-mediated immune responses - Google Patents

Method of enhancing lymphocyte-mediated immune responses

Info

Publication number
AU2002232447A1
AU2002232447A1 AU2002232447A AU3244702A AU2002232447A1 AU 2002232447 A1 AU2002232447 A1 AU 2002232447A1 AU 2002232447 A AU2002232447 A AU 2002232447A AU 3244702 A AU3244702 A AU 3244702A AU 2002232447 A1 AU2002232447 A1 AU 2002232447A1
Authority
AU
Australia
Prior art keywords
immune responses
mediated immune
enhancing lymphocyte
lymphocyte
enhancing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002232447A
Inventor
Eric A. Butz
Thibaut N. De Smedt
David H Lynch
Charles R. Maliszewski
Robert E. Miller
Elaine K. Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of AU2002232447A1 publication Critical patent/AU2002232447A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/405—Invertebrates antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2002232447A 2000-11-02 2001-10-30 Method of enhancing lymphocyte-mediated immune responses Abandoned AU2002232447A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24572100P 2000-11-02 2000-11-02
US60/245,721 2000-11-02
PCT/US2001/044834 WO2002036141A2 (en) 2000-11-02 2001-10-30 Method of enhancing lymphocyte-mediated immune responses

Publications (1)

Publication Number Publication Date
AU2002232447A1 true AU2002232447A1 (en) 2002-05-15

Family

ID=22927809

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002232447A Abandoned AU2002232447A1 (en) 2000-11-02 2001-10-30 Method of enhancing lymphocyte-mediated immune responses

Country Status (3)

Country Link
US (1) US20040247563A1 (en)
AU (1) AU2002232447A1 (en)
WO (1) WO2002036141A2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1234031B2 (en) 1999-11-30 2021-11-24 Mayo Foundation For Medical Education And Research B7-h1, a novel immunoregulatory molecule
ES2328025T3 (en) * 2001-10-09 2009-11-06 Mayo Foundation For Medical Education And Research IMPROVEMENT OF IMMUNE RESPONSES BY AGONIST ANTIBODIES 4-1 BB.
US20030166559A1 (en) 2002-01-04 2003-09-04 Desjarlais John R. Dominant negative proteins and methods thereof
US7381792B2 (en) 2002-01-04 2008-06-03 Xencor, Inc. Variants of RANKL protein
US7553930B2 (en) 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
ATE506456T1 (en) 2003-06-10 2011-05-15 David Gladstone Inst METHOD FOR TREATING LENTIVIRUS INFECTIONS
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
US20070298051A1 (en) * 2003-11-19 2007-12-27 Beth Israel Deaconess Medical Center Adjuvants Of Immune Response
WO2005113598A2 (en) * 2004-05-21 2005-12-01 Xencor, Inc. Tnf super family members with altered immunogenicity
DK3428191T3 (en) 2004-10-06 2025-01-02 Mayo Found Medical Education & Res B7-H1 AND PD-1 FOR THE TREATMENT OF RENAL CELL CARCINOMA
US8513008B2 (en) 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
EP2251418B1 (en) 2004-10-07 2021-03-17 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
EP1674077A1 (en) * 2004-12-27 2006-06-28 Université de Liège Mucoadhesive pharmaceutical compositions comprising chemoattractants
US20080019905A9 (en) * 2005-02-18 2008-01-24 Strome Scott E Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection
US20060182744A1 (en) * 2005-02-15 2006-08-17 Strome Scott E Anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof
KR20080068089A (en) * 2005-10-21 2008-07-22 지티씨바이오쎄라퓨틱스,인크. Antibodies with enhanced antibody-dependent cytotoxic activity, methods for their production and use
US10106619B2 (en) * 2006-10-04 2018-10-23 La Jolla Institute For Allergy And Immunology Virus vaccination and treatment methods with OX40 agonist compositions
ES2567704T3 (en) * 2007-07-10 2016-04-26 Apogenix Gmbh TNF superfamily colectin fusion proteins
US20110229460A1 (en) * 2008-05-01 2011-09-22 Gtc Biotherapeutics, Inc. anti-cd137 antibody as an agent in the treatment of inflammatory conditions
EP2829550B1 (en) 2009-01-09 2016-11-16 Apogenix AG Fusion proteins forming trimers
US9302005B2 (en) 2013-03-14 2016-04-05 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
US10259875B2 (en) 2013-10-01 2019-04-16 Mayo Foundation For Medical Education And Research Methods for treating cancer in patients with elevated levels of BIM
US10302653B2 (en) 2014-05-22 2019-05-28 Mayo Foundation For Medical Education And Research Distinguishing antagonistic and agonistic anti B7-H1 antibodies
EP3171896A4 (en) 2014-07-23 2018-03-21 Mayo Foundation for Medical Education and Research Targeting dna-pkcs and b7-h1 to treat cancer
JP2014218510A (en) * 2014-08-11 2014-11-20 アポゲニクスゲゼルシャフト ミット ベシュレンクテルハフツングＡｐｏｇｅｎｉｘ ＧｍｂＨ Fusion proteins forming trimers
WO2017075045A2 (en) 2015-10-30 2017-05-04 Mayo Foundation For Medical Education And Research Antibodies to b7-h1
EP3873500A4 (en) 2018-10-31 2023-01-11 Mayo Foundation for Medical Education and Research METHODS AND MATERIALS FOR THE TREATMENT OF CANCER
WO2020092736A1 (en) 2018-10-31 2020-05-07 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
WO2022036495A1 (en) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100676792B1 (en) * 1995-10-04 2007-02-02 임뮤넥스 코포레이션 Dendritic cell stimulating factor
US7150992B1 (en) * 1995-10-04 2006-12-19 Innunex Corporation Methods of preparing dendritic cells with flt3-ligand and antigen
KR20000022445A (en) * 1996-07-10 2000-04-25 크리스토퍼 엘. 와이트, 스코트 지. 홀퀴스트, 스티븐 엘. 말라스카 Method of activating dendritic cells
AU2004199A (en) * 1997-12-19 1999-07-12 Immunex Corporation Method for reducing susceptibility to hiv infection
CA2323929C (en) * 1998-04-03 2004-03-09 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
US6291661B1 (en) * 1998-07-02 2001-09-18 Immunex Corporation flt3-L mutants and method of use
WO2001015728A1 (en) * 1999-08-27 2001-03-08 University Health Network Method for activating cytotoxic t-lymphocytes (ctls) in vivo : composition comprising antibody anti cd40 (or cd40l or cd40 binding protein) and an antigen
EP1216055A2 (en) * 1999-09-30 2002-06-26 Corixa Corporation Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
EP1261366A4 (en) * 2000-02-24 2003-06-18 Univ Leland Stanford Junior ADJUVANT TREATMENT BY ACTIVATING DENDRITIC CELLS IN VIVO
ES2288952T3 (en) * 2000-05-11 2008-02-01 Baylor Research Institute COMPOSITIONS AND METHODS TO PRODUCE ANTIGEN PRESENTING CELLS.

Also Published As

Publication number Publication date
WO2002036141A3 (en) 2003-08-21
US20040247563A1 (en) 2004-12-09
WO2002036141A2 (en) 2002-05-10

Similar Documents

Publication Publication Date Title
AU2002232447A1 (en) Method of enhancing lymphocyte-mediated immune responses
AU4708601A (en) Method for enhancing immune responses in mammals
AU2002222178A1 (en) Method of indexing entities
AU7983198A (en) Improved methods for inducing an immune response
AU5551299A (en) Method of identifying proteins
AU2308900A (en) Analysis method
AU2001259667A1 (en) Electrostatographic blender assembly and method
AU2825400A (en) Two-dimensional separating method
AU2002214487A1 (en) Method for inducing apoptiosis
AU3179999A (en) Methods to treat undesirable immune responses
AU2001237530A1 (en) Method
AU1533099A (en) Methods for evaluating immune function
AU2002330561A1 (en) Reagent and method for perfluoroalkylation
AU2001241636A1 (en) Halotherapy method
AU2001230253A1 (en) Processing method
AU2002216100A1 (en) Dormancy - induced mycobacterium proteins
AU2002366026A1 (en) Frying method
AU2001237633A1 (en) Method of identifying modulators of presenilin
AU2001232047A1 (en) Sample preparation method
AU2945599A (en) Immune response
AU2002213695A1 (en) Method of genomic analysis
AUPP371798A0 (en) Parasite antigens
AU2001249776A1 (en) Method of polycarbonate preparation
AU2003268688A1 (en) Method of inducing immune responses
AU2002228975A1 (en) Method